Aldeyra Therapeutics, INC Form 4 insider transactions

Director Ben Bronstein acquired stock options in Aldeyra Therapeutics, Inc. on June 4, 2024.

Gary M. Phillips, a director at Aldeyra Therapeutics, acquired stock options on June 4, 2024, exercisable one year from the grant date, contingent upon continued service on the board and its committees.

Stephen Machatha, Chief Development Officer of Aldeyra Therapeutics, amends his Form 4 filing to accurately reflect a stock sale for tax purposes and an omission of shares acquired through the Employee Stock Purchase Plan.

Bruce Greenberg, Interim CFO of Aldeyra Therapeutics, sold shares to cover tax obligations and amended a previous filing to correct an omission regarding shares acquired through the Employee Stock Purchase Plan.

Perceptive Advisors and related entities report purchasing additional shares of Aldeyra Therapeutics, increasing their beneficial ownership.

Perceptive Advisors LLC, along with related entities and Joseph Edelman, reported purchasing additional shares of Aldeyra Therapeutics, Inc. between April 1 and April 3, 2024, increasing their indirect holdings.

Bruce Greenberg, Interim CFO of Aldeyra Therapeutics, acquired stock options and sold shares to cover tax obligations.

Stephen Machatha, Chief Development Officer of Aldeyra Therapeutics, sold shares to cover tax obligations and acquired stock options.

Aldeyra Therapeutics CEO Todd C. Brady sold shares for tax purposes and received a stock option grant.